Amitraz Poisoning: An Under Recognised and Unusual Poisoning: A Case Report

Authors
Sudha.S¹, Saritha K Narayanan², Rakesh Sebastian X³, Periyasamy K⁴ Ramakrishna Rao.M⁵

Abstract
Amitraz poisoning is an unusual, but definitely with a potential to become lethal poisoning. Amitraz is a Triazapentadiene – an α₂ adrenergic agonist used widely in veterinary and agricultural field for the treatment of Ectoparasitic infestation. We report a case presented to our ER after two hours of ingestion of AMITRAZ. On examination patient was comatose with response to only deep painful stimuli. She was also in bradycardia, hypotension and metabolic acidosis. The patient was managed with symptomatic treatment. Patient’s condition started to improve after 18 hrs of admission and she was discharged after 4 days. Though Amitraz poisoning can be fatal, if identified and treated well within time, even with minimal symptomatic management we can save the patient to complete recovery.

Keywords: Amitraz, α₂ Agonist, CNS depression.

Introduction
Amitraz (Fig.1) is a pesticide used worldwide. It is a triazapentadiene¹ compound which is a centrally acting α₂ adrenergic agonist

It is a member of formamidane pesticide. Commercial formulations of Amitraz generally contain 12.5 – 50% of the drug in organic solvents especially xylene is used as a solvent. A limited number of human intoxication cases have been published in literature. Poisoning from Amitraz is under recognized even in areas where it is widely available.

Potentially serious side effects have been reported in cases exposed to the product when left untreated or unnoticed however if treated early this poison carries a very good prognosis.

Case Report
16 years old female was brought to us following ingestion of 10ml of Amitraz 12.5% mixed with water after 3hrs of consumption. The relatives
noticed that the patient was unresponsive even after 45 min post consumption hence they brought her to us. She had 3 episodes of vomiting prior to ER admission. Patient was not having any significant medical ailments before and she was not on any regular medication. At the time of presentation she was unconscious with Glasgow coma scale of 6/15. She had a pulse rate of 52/mint and blood pressure of 88/60mm Hg. Her respiratory rate was 16/mint with temperature of 98.4°F. Her oxygen saturation was 98% with 6L/min of oxygen supplied via facemask. Motor system examination revealed hypotonia of all four limbs with diminished reflexes. There was no fasciculation. Plantar reflex was normal bilaterally. Pupils were bilaterally constricted with size 1.5mm reacting to light. Optic fundus examination was normal. Further detailed neurological examination could not be elicited. Examination of other systems was normal. Gastric decontamination was done using gastric lavage and activated charcoal. Blood sample was taken for analysis. The investigation profile comprising of complete blood count, liver and renal function tests, serum electrolytes were normal. Random blood sugar level was 195 mg/dl. Arterial blood gas analysis showed metabolic acidosis (Fig. 2) which improved progressively in serial arterial blood gas analysis. CT brain was normal. Electrocardiogram revealed sinus bradycardia (Fig. 3).

Serum cholinesterase level was done to rule out organophosphorous poisoning and was normal. Hence she was treated symptomatically. She had persistent bradycardia with heart rate of 46-58/min. However her heart rate was maintained with intravenous Atropine boluses. Only symptomatic treatment and supportive measures were given to the patient. She regained consciousness and responded to oral commands after 16 hrs of intensive care. The patient was then shifted out of ICU safely on 3rd day of admission due to fast recovery. On the 5th day of admission was discharged from the hospital with good health after proper counseling.

Mechanism of Action of the compound
Amitraz exerts its action on central nervous system by stimulation of central α2 adrenergic receptors and it produce effect in the form of sleepiness, drowsiness or complete loss of consciousness depending on the dose of toxin consumed. There was a positive correlation observed between the amount of Amitraz consumed and duration of CNS depression. Amitraz exposure causes constriction of pupil[3] at
lower doses but may cause dilatation at higher doses by stimulation of α₂ adrenergic receptors and its vagomimetic activity produces bradycardia, hypotension and arrhythmias. Amitraz and its active metabolites inhibit insulin secretion and stimulate glucagon release producing a hyperglycemic state.

**Discussion**

Amitraz is a pharmaceutical product used worldwide for the treatment of ectoparasitic infestation; it produces toxic effect in animals and humans when ingested, inhaled or after skin exposure. Studies in animals showed that oral lethal dose (LD50) as 523-800mg/Kg in rats and 1600mg/Kg in mice. The toxic effect of Amitraz including sedation, bradycardia and hypotension occur due to α₂ adrenergic receptor stimulation and thus its mimics clonidine like syndrome. Hyperglycemia was detected in our case as reported in previous studies. However CNS manifestations were more profound in our case. The recovery time from CNS depression took about 16hrs with no left neurological deficit.

The co-existence of Miosis, respiratory depression, bradycardia often mislead physician into diagnosing the patient with OPC poisoning. Certain features point towards Amitraz poisoning as opposed to OPC toxicity. These included presence of hyperglycemia and reduced gastrointestinal motility with absence of fasciculation or hypersecretory state. Serum cholinesterase levels also will be normal which will be usually low in OPC poisoning.

Though there is no specific antidote for this toxin. It has an excellent prognosis even with supportive management if recognized early and given a prompt treatment.

**Conclusion**

This case report throws considerable light on the management of Amitraz poisoning with emphasis on good prognosis with early recognition and timely supportive management. There was no randomized controlled trial available till now hence no conclusions can be drawn on the ideal management strategy for Amitraz poisoning. In our case we would like to emphasize that the incidence of Amitraz intoxication is increasing day by day due to its worldwide use and easy availability. Though there is no specific antidote for this toxin, it carries an excellent prognosis with supportive management.

**Reference**